Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 3:52 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2113–2136 of 13,471 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: Ovarian Neoplasms, Colorectal Neoplasms, Melanoma, Small Cell Lung Cancer, Liposarcoma
Interventions: Ionizing radiation (IR) therapy, Ionizing radiation (IR); Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 19 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetic Retinopathy, Diabetic Macular Edema, DME
Interventions: Triamcinolone Acetonide; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Congenital Hyperinsulinism, Insulinoma
Interventions: Fluorodopa F 18; Drug
Lead sponsor: Cook Children's Health Care System; Other
Eligibility: Up to 18 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2028
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Hypertension, Type 2 Diabetes, Metabolic Syndrome, Smoking, High Cholesterol, PreDiabetes, Prehypertension
Interventions: Project WHADE: A Partner-Based Physical Activity Program for Women; Behavioral
Lead sponsor: Rowan University; Other
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Glassboro, New Jersey

Conditions: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Bladder Cancer, Uterine Cancer, Kidney Cancer, Renal Pelvis Cancer, Pancreatic Cancer, Liver Cancer, Stomach Cancer, Ovarian Cancer, Esophageal Cancer
Interventions: Blood Sample Collection; Other
Lead sponsor: Exact Sciences Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 5,133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 119
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 106 more

Conditions: Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders
Interventions: Ramelteon, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes Mellitus
Interventions: FK614; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 25 Years to 70 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 36
States / cities: Ozark, Alabama • Tucson, Arizona • Cypress, California + 29 more

Conditions: Gynecomastia, Endocrine System Diseases
Interventions: No Intervention; Other
Lead sponsor: Nutraceuticals Research Institute; Other
Eligibility: 2 Years to 15 Years
Enrollment: 2,000 participants
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Franklin, Tennessee

Conditions: Pancreatic Cancer Metastatic, Pancreatic Cancer Stage IV, Stage IV Pancreatic Cancer
Interventions: SBP-101, nab-paclitaxel, Gemcitabine Injection; Drug
Lead sponsor: Panbela Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 3
States / cities: La Jolla, California • Gainesville, Florida • Rochester, New York

Conditions: PCOS (Polycystic Ovary Syndrome)
Interventions: Ketogenic diet, Exogenous Ketone Supplement; Other · Dietary Supplement
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Diabetes Mellitus, Type 2
Interventions: Exenatide once weekly suspension, Exenatide twice daily; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 377 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 58
States / cities: Muscle Shoals, Alabama • Mesa, Arizona • Phoenix, Arizona + 52 more

Conditions: Malignant Ovarian Epithelial Tumor, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Refractory Fallopian Tube Carcinoma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma
Interventions: Akt/ERK Inhibitor ONC201, Paclitaxel, Questionnaire Administration; Drug · Other
Lead sponsor: Ira Winer; Other
Eligibility: 18 Years and older · Female only
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: Detroit, Michigan • Flint, Michigan

Conditions: Mesothelioma, Pancreatic Cancer, NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions: ODM-212, Ipilimumab and nivolumab, Gemcitabine and nab-paclitaxel, sotorasib; Drug
Lead sponsor: Orion Corporation, Orion Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 5
States / cities: Los Angeles, California • Orange, California • Fort Worth, Texas + 2 more

Conditions: Hypogonadism
Interventions: TSX-002; Drug
Lead sponsor: TesoRx Pharma, LLC; Industry
Eligibility: 18 Years to 70 Years · Male only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: San Diego, California

Conditions: Neoplasms, Lung Neoplasms, Colon Neoplasms, Breast Neoplasms, Pancreatic Neoplasms, Prostate Neoplasms, Kidney Neoplasms, Liver Neoplasms, Rectal Neoplasms, Hematologic Neoplasms, Multiple Myeloma, Myelodysplastic Syndromes, Ovarian Neoplasms, Bladder Neoplasms, Testicular Neoplasms, Endometrial Neoplasms, Brain Neoplasms, Biliary Tract Neoplasms, Head and Neck Neoplasms, Uterine Cervical Neoplasms, Skin Neoplasms, Melanoma, Gastric Neoplasms, Anal Neoplasms, Sarcoma
Interventions: Provider determined; Other
Lead sponsor: CureOne; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Idaho Falls, Idaho

Conditions: Wounds and Injuries
Interventions: Allevyn Life, Foam dressing with an integrated adhesive border; Device
Lead sponsor: Smith & Nephew, Inc.; Industry
Eligibility: 65 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: Tustin, California • Wichita, Kansas • McAllen, Texas

Conditions: Ovarian Cancer
Interventions: ThermalCore Hyperthermia System; Device
Lead sponsor: ThermalCore Inc; Industry
Eligibility: 18 Years to 69 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: San Jose, California

Conditions: Insulin-dependent Diabetes Mellitus, Diabetes Mellitus
Interventions: IBC-VS01, IBC-VS01 placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 35 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Diabetes Mellitus, Type 2
Interventions: Educational Materials; Procedure
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 740 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 42
States / cities: Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 36 more

Conditions: Solid Tumors With PTCH1 Loss-of-function Mutations
Interventions: ENV-101 (taladegib); Drug
Lead sponsor: Endeavor Biomedicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 16
States / cities: Los Angeles, California • Santa Rosa, California • Tampa, Florida + 13 more

Conditions: Diabetes Complications, Diabetic Neuropathies
Interventions: Muscle power, balance perturbation, aerobic exercise; Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 55 Years to 80 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: celecoxib, paclitaxel; Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions: Anetumab Ravtansine, Biopsy Procedure, Biospecimen Collection, Gemcitabine Hydrochloride, Ipilimumab, Nivolumab; Biological · Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 44
States / cities: Birmingham, Alabama • Duarte, California • Irvine, California + 35 more

Conditions: Diabetes, Hypertension, Nutrition Poor
Interventions: Produce delivery, Cooking classes; Other
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 64 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Search by objective public record fields.

An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation

Treatment of Diabetic Macular Edema: Triamcinolone Injections Vs. Laser Photocoagulation

Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma

Project WHADE: A Partner-Based Physical Activity Program for Women

Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors

Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia

Trial of FK614 in Type 2 Diabetics Inadequately Controlled on a Sulfonylurea

Skincare Products and Environmental Health

Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer

Symptoms of Polycystic Ovarian Syndrome Ameliorated by Keto-Adaptation Pilot

Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes

ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer

A 2-part Phase 1/2 Open-label Trial on ODM-212

Oral Testosterone for the Treatment of Hypogonadism in Males

CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice

Managing Wounds With Allevyn Life in a Home Health Care Environment

A Phase 1 Trial of Perfusion Induced Systemic Hyperthermia (PISH) Over Multiple Cycles for Terminal Ovarian Cancer

Evaluation of a Diabetes Vaccine in Newly Diagnosed Diabetics

US Inhaled Insulin Therapeutic Choice Questionnaire Study

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Enhance Balance and Mobility in People With Type 2 Diabetic Peripheral Neuropathy

Paclitaxel and Celecoxib in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer

Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer

The Produce Drop: Using Food as Medicine to Lower A1C Levels and Blood Pressure